By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ocular Therapeutix, Inc. 

204 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-895-3235 Fax: 781-895-3236


SEARCH JOBS


Industry
Biotechnology






Company News
Ocular Therapeutix (OCUL) Announces FDA Acceptance Of NDA Resubmission For DEXTENZA For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery 2/22/2017 6:23:25 AM
Ocular Therapeutix (OCUL) Eyes $25 Million in Public Offering 1/24/2017 6:46:39 AM
Ocular Therapeutix (OCUL) Release: Biopharma Resubmits NDA For DEXTENZA For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery 1/23/2017 7:47:39 AM
Ocular Therapeutix (OCUL) Jumps on More Positive Study Data for Dextenza 1/4/2017 6:45:19 AM
Ocular Therapeutix (OCUL) Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA 11/14/2016 11:39:22 AM
Ocular Therapeutix (OCUL) Reports Third Quarter 2016 Financial Results And Provides Corporate Update 11/9/2016 10:45:26 AM
Ocular Therapeutix (OCUL) To Hold Third Quarter 2016 Financial Results Conference Call On Wednesday, November 9, 2016 11/2/2016 10:40:13 AM
Ocular Therapeutix (OCUL) Strengthens Management Team With The Appointment Of Andy Hurley As Chief Commercial Officer 10/20/2016 11:05:52 AM
Ocular Therapeutix (OCUL) Outlines Development Strategy For Its Sustained Release Intravitreal Depots To Address Serious Retinal Diseases 10/13/2016 12:39:07 PM
Regeneron (REGN) Bets $315 Million on Ocular Therapeutix (OCUL) for an Upgraded Form of Eylea 10/13/2016 5:30:27 AM
12345678910
//-->